COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca, Jon Salmanton‐García, Paolo Corradini, Francesco Marchesi, Alba Cabirta, Roberta Di Blasi, Rémy Duléry, Sylvain Lamure, Francesca Farina, Barbora Weinbergerová, Josip Batinić, Anna Nordlander, Alberto López‐García, Ľuboš Drgoňa, Ildefonso Espigado, Iker Falces‐Romero, Ramón García‐Sánz, Carolina García‐Vidal, Anna Guidetti, Nina Khanna, Austin Kulasekararaj, Johan Maertens, Martin Hoenigl, Н Н Климко, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Oliver A. Cornely, Livio Pagano
Abstract
Key Points The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.